This article is more than 5 years old. Information may no longer be current.

Cancer drug can lead to irreversible ocular damage

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Patients receiving docetaxel for the treatment of metastatic breast cancer should be monitored frequently to avoid potentially irreversible ocular damage, warn two physicians.

Craig A. Skolnick, MD, and Donald J. Doughman, MD, of Miami’s Bascom Palmer Eye Institute reported on the case of a 58-year-old woman with metastatic breast cancer. While on her course of docetaxel treatment, she developed erosive conjunctivitis and punctal stenosis. Once the docetaxel treatment was discontinued, the erosive conjunctivitis resolved, but the punctal stenosis persisted.

The case study is published in Eye & Contact Lens: Science and Clinical Practice.